Background and Purpose: Antithombotics are the mainstay of treatment in primary and secondary
Introduction
Even though use of antithrombotic medications for primary and secondary prevention of cardiovascular disease is increasing, many patients with indications are still not receiving antithrombotic medications and suffer an acute ischemic stroke [1] . It also remains unclear if prior therapy can also improve outcomes from those still having an acute ischemic stroke. Possible mechanisms for such a benefit include:
attenuating the volume of the initial thrombus, preventing clot propagation, and reducing the risk of early recurrent thrombosis or embolism.
Despite theoretical mechanisms for benefit, existing evidence on the topic is conflicting. Kwok and colleagues found that prior antithrombotic use was not associated with reduced mortality up to one year after stroke presentation [2] . In contrast, a large registry from Canada reported a beneficial association between prior use of antithrombotics and improved functional outcome [3] [4] . Indeed, recent studies found a reduction in initial stroke severity in previous antiplatelet users in ischemic stroke [5] [6] , suggesting prior antithrombotic therapy may moderate ischemic stroke evolution from the earliest moments of onset. To date, however, all these studies were small or moderate in size and some of these conflicts may be due to unstable estimates.
Using data from the American Heart Association/American Stroke Association (AHA/ASA) Get with the Guidelines-Stroke (GWTG-Stroke) database, our study aims were to: (1) describe characteristics of ischemic stroke patients by receipt or non-receipt of antithrombotic medication prior to stroke; (2) determine whether pre-stroke antithrombotic use is related to outcomes at discharge, and whether this relationship varies with indication for antithrombotic use; and (3) determine whether prior warfarin use is associated with outcomes at discharge among patients with atrial fibrillation (AF) or flutter, taking INR control into account.
Methods
The AHA/ASA GWTG-Stroke database data collection methods have been previously described [7] [8] [9] [10] . In brief, 1661 hospitals used an Internet-based "Patient Management Tool" (Quintiles, Cambridge, MA) to enter data, receive decision support, and obtain feedback via on demand reports of performance on quality measures and recorded data from consecutive admissions for acute ischemic stroke. There were a total of 624,883 patients with ischemic stroke at 1,705 participating centres between 1st October 2011 and 31st March 2014. Of them 19,381 were transferred to another acute facility, left against medical advice, or had no data on discharge status; 63,738 had missing data on prior antithrombotic use, and further 771 patients were excluded due to data on vascular indication for use of antithrombotics was missing.
Trained hospital personnel abstracted data using the Internet-based Patient Management Tool with standardized data definitions and detailed coding instructions. The Internet-based system performs checks to ensure that the reported data are complete and internally consistent. In addition, data quality is monitored for both completeness and accuracy. Hospitals that participate must receive approval through their local institutional review boards or a waiver of individual consent under the common rule. Quintiles were based on American Hospital Association data [10] . Past medical history was defined on the basis of pre-existing conditions, with the exclusion of conditions that were newly diagnosed during the hospital stay.
Prior antithrombotic use was defined as any anticoagulant or antiplatelet use before the index stroke.
Patients were considered to have a vascular indication for antithrombotic use if their medical history included coronary artery disease (CAD), previous stroke or transient ischemic attack (TIA), or atrial fibrillation or flutter. Our study examined patient-relevant outcomes of in-hospital mortality, discharge to home, ability to ambulate independently at discharge, disability at the time of discharged defined using modified Rankin scale (mRS ≥2) and acute hospital length of stay (LOS).
Statistical analysis
Analyses were carried out using SAS version 9.3 or higher (SAS Institute, Cary NC). We compared the baseline characteristics for patients by (a) prior use of antithrombotic (yes vs. no) and (b) prior use of antithrombotic (yes vs. no) and indication (any vs. none) (4 groups). Differences are compared with Pearson chi-square tests for categorical and Wilcoxon rank-sum and Kruskal-Wallis tests for continuous variables and data are presented descriptively.
To evaluate associations, multivariable logistic regression was used for binary outcomes. Multiple regression was used for LOS, which was transformed using the natural log to achieve approximate normality. In addition to the term for prior antithrombotic use, each model also contained a term for antithrombotic indication, and a term for the interaction between them. Models were adjusted for covariates at admission including age, sex, race, BMI, medical history, on-hours arrival, and site characteristics. Missing values of covariates were imputed using multiple imputation (25 imputations).
Generalized estimating equations (GEEs) were used to account for clustering within hospitals.
We present prior antithrombotic odds ratios within indication subgroups if the interaction between antithrombotic use and indication is significant and if not, present separate antithrombotic and indication odds ratios (i.e., main effects). For LOS outcome the interaction between prior antithrombotic use and indication was significant, and thus the ratio of expected LOS for the two groups is reported i.e. the data are presented as the ratio of expected LOS in the first group compared to the second, that is, (expected days in group 1)/ (expected days in group 2). Therefore, for LOS outcome, risk relationships are shown for each variable within levels of the other variable.
Because NIHSS is missing in a proportion of patients (23%) a sensitivity analysis was performed in which these models were repeated, including NIHSS as a covariate, in the subset of patients with available NIHSS data.
Persistent or paroxysmal AF/flutter during the index admission and previous medical history of AF/flutter were used to define AF/flutter in this study. To determine whether prior warfarin use is associated with outcomes among patients with AF/flutter, taking INR control into account, patients were grouped as (1) prior use of anticoagulants with INR > 1.4 at admission, (2) prior use of anticoagulants with INR ≤ 1.4 at admission, and (3) no anticoagulants prior to admission. Patients who were on an anticoagulant but who do not have INR data were excluded from this analysis. Models used were the same as for the main analysis, except that the three warfarin groups were included in the model in place of the antithrombotic and indication terms, an additional term was added for non-anticoagulant antithrombotics (e.g., aspirin and other antiplatelet drugs), and patients taking new oral anticoagulants (NOACs) were excluded. Each warfarin group was compared to the no-warfarin group (reference group).
Results
A total of 540,993 patients at 1,661 sites admitted with an ischemic stroke during the study period were included in the current study. Over half (53.8%) were receiving an antithrombotic agent (either an antiplatelet/combination or an anticoagulant); 253,552 (46.9%) on were taking antiplatelet drugs and 57,543 (10.6%) were taking an anticoagulant (the sum total is greater than 53.8% because some patients were taking both) (see Supplementary Figure for The characteristics of all patients included in the analyses and then separately for those who received antithrombotics prior to the index ischemic stroke and those who did not were shown in Table 1 . With large numbers the p values are highly significant between the two populations. People who did not take any antithrombotic prior to stroke were younger, more likely to be female, less likely to be Caucasian, more likely to have abnormal lipid profile, more likely to be a current smoker, but with lower prevalence of co-morbid medical conditions including previous history of stroke and AF/flutter, and were more likely to be ambulatory independently prior to stroke. Although many of the acute biochemistry and haematological parameters, and site characteristics, were statistically significantly different between these groups, the magnitudes of differences were negligible. use, regression models (with full adjustment) demonstrate that patients taking an antithrombotic prior to the index stroke were less likely to die during the hospitalization and more likely to be discharged to home, able to ambulate independently, and better functional outcomes at discharge compared with patients who were not on an antithrombotic. Supplementary Table II shows that patients with a vascular indication for antithrombotic use (medical history of CAD, previous stroke or TIA, or atrial fibrillation or flutter) were more likely to have unfavourable/negative outcomes than patients without an indication.
There were no significant interactions between antithrombotic use and prior indication for use, indicating that the lower rate of in-hospital death with antithrombotic use was similar for patients with and without a vascular indication for use. Discharge outcome to home among patients discharged alive, and ambulatory status among patients able to ambulate independently prior to the event, showed results which were consistent with the models in the larger set of patients.
Length of stay outcome analysis shows patients taking an antithrombotic prior to stroke had a shorter expected hospital stay than patients not on an antithrombotic prior to the event. The significant interaction indicates that the expected relative length of stay depends on whether or not the patient had an indication -there is more of an associated reduction in LOS, with antithrombotic compared to without, where there is an indication (see Table 2 ).
Supplementary Tables III & IV
show the results in a subset of patients in whom NIHSS was available with additional adjustment for NIHSS score. Results are generally consistent with those in the full cohort, except for LOS, which here does not have a significant interaction between antithrombotic and the presence or absence of an indication for its use. Table V) . Table 3 demonstrates that patients on warfarin with INR>1.4 had better outcomes than patients not on warfarin. Patients on warfarin with INR ≤ 1.4 had a higher risk of in-hospital death, lower likelihood of being discharged home, and a longer length of hospital stay, compared to patients not on warfarin prior to stroke, but a similar probability of being able to ambulate independently and having a low mRS score at the time of discharge.
Discussion
To the best of our knowledge, this study is the largest to examine the association between prior antithrombotic use and important and relevant outcomes in patients admitted with an acute ischemic stroke. We found that the prior use of antithrombotics was associated with a favourable outcome for all outcomes assessed highlighting an important point that antithrombotics not only have effect on vascular outcome but also may reduce the severity of vascular outcomes. Associations between prior antithrombotic medication use and better post-stroke outcomes were seen across patient subgroups. No significant interaction between antithrombotic use and indication was observed except for LOS outcome.
To date, the literature around the impact of prior antithrombotic use on stroke outcome has been inconsistent and shown conflicting results. However, they were limited by relatively small sample size (Sanosian et al, n=260) [11] (Vibo et al, n=433) [12] , or focused on mortality alone [2] [12], or in a particular patient population or of certain age [13] , or examined the stroke severity only [14] . Relatively larger studies again showed conflicting results [2] Table 2 ). This use may be due to other appropriate indications but could also reflect self-medication, which would be concerning due to the potential harm from drug side effects.
White et al [1] highlighted similar mismatches and the fact whilst half of strokes cases were on antithrombotics and yet developed stroke, half of stroke patients might have been identified as high risk and been prescribed an antithrombotic medication that would have prevented a substantial number of stroke events. This, in combination with our current study findings, further strengthens the argument to base antithrombotic medication use on improved risk prediction scores. Indeed, Loke et al [16] recently highlighted the lack of sensitivity of existing cardiovascular risk prediction tools in reliably identifying those groups of patients who are most likely to subsequently develop cardiovascular (CV) adverse events [17] . Most recent guidelines from US [18] , Europe [19] , UK [20] and ATP III [21] mainly focused on CV risk factors and use of antiplatelets in primary prevention was less well focused perhaps due to presumed adherence to established guidance.
The strengths of our study include the large sample size and prospective data collection. One of the key strengths of the paper includes the robust statistical analysis with ability to control for potential confounders as well as ability to understand the confounding effect by indication through analysis of indication for antithrombotic vs. their effect on the outcomes examined. We were able to examine the outcomes by prior antithrombotic use as well as by vascular indication. We were also able to examine the outcomes by prior warfarin use and INR among patients with AF/flutter. Further, we were able to analyse the data taken into account of the stroke severity at onset (e.g., National Institutes of Health Stroke Scale (NIHSS) score) in this current report.
Our study has some limitations. As a hospital-based registry some cases of stroke might not have been included, such as patients who died before admission. Patients and hospitals may not be entirely representative of the U.S population but the sample population is comparable to all US patients hospitalized with stroke [22] . Residual measured and unmeasured confounders may account for some of these findings such as factors that could have influenced prior use of antithrombotic therapy and adherence to prescribed therapy. For example, those who use antithrombotic agents may have a 'healthy user' effect or greater use of health care. Whilst a substantial proportion of patients had missing data on NIHSS and that was due to non-random missing, repeating the analyses in those who had NIHSS data yielded the similar results. As an observational study the causality cannot be assumed. Nonetheless, the observed associations have plausible explanations, as we alluded to in the introduction.
In summary, using the AHA/ASA GWTG-Stroke registry data with over half a million of ischemic stroke patients, we present evidence that prior antithrombotic use was associated with favorable outcomes in ischemic stroke and thus highlights the importance of primary and secondary stroke prevention with antithrombotic medications when indicated. A substantial proportion of patients in our study sustained stroke despite being on antithrombotic agents and the fact that patients with INR <1.4 among people with AF/flutter had worse outcomes suggests the urgent need to address issues of medication compliance, and adequate anticoagulation in stroke prevention. Ensuring appropriate use of antithrombotics at a population level may have substantial benefit to patients with stroke and health economy in a global scale. Dr Fonarow is a member of the GWTG Executive Committee; has served as a consultant to Janssen (modest), receives research support from PCORI (significant), and is an employee of UCLA, which holds a patent on retriever devices for stroke.
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